Forest Cuts Forecast as Copycats Take More Lexapro Sales

Forest Laboratories Inc. cut its fiscal 2013 earnings forecast because sales of Lexapro, a pill to treat depression, are being lost to Teva Pharmaceutical Industries Ltd.’s generic version.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.